Composition containing a gold (I) complex and cancer cells

A composition, comprising:

• a gold(I) complex represented by formula (I):
• a salt thereof, a solvate thereof, or a combination thereof;
• cancer cells;
• and
• at least one chemotherapeutic agent selected from the group consisting of aflibercept, asparaginase, bleomycin, busulfan, carmustine, chlorambucil, cladribine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, doxorubicin, etoposide, fludarabine, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitoxantrone, pentostatin, procarbazine, topotecan, vinblastine, vincristine, retinoic acid, oxaliplatin, carboplatin, 5-fluorouracil, teniposide, amasacrine, docetaxel, paclitaxel, vinorelbine, bortezomib, clofarabine, capecitabine, actinomycin D, epirubicin, vindesine, methotrexate, 6-thioguanine, tipifarnib, imatinib, erlotinib, sorafenib, sunitinib, dasatinib, nilotinib, lapatinib, gefitinib, temsirolimus, everolimus, rapamycin, bosutinib, pzopanib, axitinib, neratinib, vatalanib, pazopanib, midostaurin, enzastaurin, trastuzumab, cetuximab, panitumumab, rituximab, bevacizumab, mapatumumab, conatumumab, and lexatumumab;
• wherein R1 and R2 are alkyl groups independently selected from the group consisting of methyl, ethyl and isopropyl;
• R3, R4, and R5 are independently selected from the group consisting of an optionally substituted C1-C3 alkyl, an optionally substituted C3-C5 cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted arylolefin, an optionally substituted vinyl;
• and
• with the proviso that R1, R2, R3, R4, and R5 are not each an ethyl.